Cargando…

Use of In Vivo Imaging and Physiologically-Based Kinetic Modelling to Predict Hepatic Transporter Mediated Drug–Drug Interactions in Rats

Gadoxetate, a magnetic resonance imaging (MRI) contrast agent, is a substrate of organic-anion-transporting polypeptide 1B1 and multidrug resistance-associated protein 2. Six drugs, with varying degrees of transporter inhibition, were used to assess gadoxetate dynamic contrast enhanced MRI biomarker...

Descripción completa

Detalles Bibliográficos
Autores principales:	Melillo, Nicola, Scotcher, Daniel, Kenna, J. Gerry, Green, Claudia, Hines, Catherine D. G., Laitinen, Iina, Hockings, Paul D., Ogungbenro, Kayode, Gunwhy, Ebony R., Sourbron, Steven, Waterton, John C., Schuetz, Gunnar, Galetin, Aleksandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057977/ https://www.ncbi.nlm.nih.gov/pubmed/36986758 http://dx.doi.org/10.3390/pharmaceutics15030896

Ejemplares similares

Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats
por: Scotcher, Daniel, et al.
Publicado: (2021)

Coproporphyrin I as an Endogenous Biomarker to Detect Reduced OATP1B Activity and Shift in Elimination Route in Chronic Kidney Disease
por: Takita, Hiroyuki, et al.
Publicado: (2022)

Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B‐Mediated Drug–Drug Interactions Using Population Pharmacokinetic Modeling and Simulation
por: Barnett, Shelby, et al.
Publicado: (2018)

Model‐Based Drug–Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy
por: Cleary, Yumi, et al.
Publicado: (2021)

Physiologically‐Based Pharmacokinetic Modelling of Creatinine‐Drug Interactions in the Chronic Kidney Disease Population
por: Takita, Hiroyuki, et al.
Publicado: (2020)

Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug–Drug Interactions in Children
por: Cleary, Yumi, et al.
Publicado: (2023)

PBPK Simulation-Based Evaluation of Ganciclovir Crystalluria Risk Factors: Effect of Renal Impairment, Old Age, and Low Fluid Intake
por: Scotcher, Daniel, et al.
Publicado: (2021)

A population pharmacokinetic model for simvastatin and its metabolites in children and adolescents
por: Ogungbenro, Kayode, et al.
Publicado: (2019)

PBPK Model of Coproporphyrin I: Evaluation of the Impact of SLCO1B1 Genotype, Ethnicity, and Sex on its Inter‐Individual Variability
por: Takita, Hiroyuki, et al.
Publicado: (2021)

Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance
por: Scotcher, Daniel, et al.
Publicado: (2016)

Population pharmacokinetic modeling and simulation to support qualification of pyridoxic acid as endogenous biomarker of OAT1/3 renal transporters
por: Ahmad, Amais, et al.
Publicado: (2021)

Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations
por: Scotcher, Daniel, et al.
Publicado: (2017)

Mechanistic Models as Framework for Understanding Biomarker Disposition: Prediction of Creatinine‐Drug Interactions
por: Scotcher, Daniel, et al.
Publicado: (2020)

Effect of Chronic Kidney Disease on the Renal Secretion via Organic Anion Transporters 1/3: Implications for Physiologically‐Based Pharmacokinetic Modeling and Dose Adjustment
por: Tan, Shawn Pei Feng, et al.
Publicado: (2022)

A “middle‐out approach” for the prediction of human drug disposition from preclinical data using simplified physiologically based pharmacokinetic (PBPK) models
por: Yau, Estelle, et al.
Publicado: (2023)

In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition
por: Murata, Yukiko, et al.
Publicado: (2022)

Repeatability and reproducibility of longitudinal relaxation rate in 12 small-animal MRI systems
por: Waterton, John C., et al.
Publicado: (2019)

Assessment of gadoxetate DCE-MRI as a biomarker of hepatobiliary transporter inhibition
por: Ulloa, Jose L, et al.
Publicado: (2013)

Impact of tumour size measurement inter-operator variability on model-based drug effect evaluation
por: Lombard, Aurélie, et al.
Publicado: (2020)

A Novel Physiologically Based Model of Creatinine Renal Disposition to Integrate Current Knowledge of Systems Parameters and Clinical Observations
por: Scotcher, Daniel, et al.
Publicado: (2020)

Microsomal and Cytosolic Scaling Factors in Dog and Human Kidney Cortex and Application for In Vitro-In Vivo Extrapolation of Renal Metabolic Clearance
por: Scotcher, Daniel, et al.
Publicado: (2017)

Ex vivo gadoxetate relaxivities in rat liver tissue and blood at five magnetic field strengths from 1.41 to 7 T
por: Ziemian, Sabina, et al.
Publicado: (2020)

Investigation of simplified physiologically‐based pharmacokinetic models in rat and human
por: Yau, Estelle, et al.
Publicado: (2023)

In Vitro Assessment of Uptake and Lysosomal Sequestration of Respiratory Drugs in Alveolar Macrophage Cell Line NR8383
por: Ufuk, Ayşe, et al.
Publicado: (2015)

Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size data
por: Wendling, Thierry, et al.
Publicado: (2016)

Drug–Target Kinetics in Drug Discovery
por: Tonge, Peter J.
Publicado: (2017)

Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Effect of Chronic Kidney Disease on the Disposition of Hepatic CYP2C8 and OATP1B Drug Substrates
por: Tan, Ming‐Liang, et al.
Publicado: (2018)

Development of a sensitive biochemical assay for the detection of tofacitinib adherence
por: Church, Stephanie, et al.
Publicado: (2023)

Drug transport kinetics of intravascular triggered drug delivery systems
por: ten Hagen, Timo L. M., et al.
Publicado: (2021)

Kinetic Determination of Ribavirin in Drug Formulations
por: El-Brashy, A. M., et al.
Publicado: (2007)

Imaging Biomarkers in Animal Models of Drug-Induced Lung Injury: A Systematic Review
por: Mahmutovic Persson, Irma, et al.
Publicado: (2020)

Multi-scale modeling of drug binding kinetics to predict drug efficacy
por: Clarelli, Fabrizio, et al.
Publicado: (2019)

Drug repurposing for Dravet syndrome in scn1Lab (−/−) mutant zebrafish
por: Sourbron, Jo, et al.
Publicado: (2019)

Modeling of chemical kinetics and reactor design /
por: Coker, A. Kayode
Publicado: (2001)

Quantifying heterogeneity to drug response in cancer–stroma kinetics
por: Alemanno, Francesco, et al.
Publicado: (2023)

Does “Birth” as an Event Impact Maturation Trajectory of Renal Clearance via Glomerular Filtration? Reexamining Data in Preterm and Full‐Term Neonates by Avoiding the Creatinine Bias
por: Salem, Farzaneh, et al.
Publicado: (2020)

Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models
por: Danhof, Meindert
Publicado: (2015)

Are improper kinetic models hampering drug development?
por: Walsh, Ryan
Publicado: (2014)

HCV Kinetic Models and Their Implications in Drug Development
por: Nguyen, THT, et al.
Publicado: (2015)

Drug Release Kinetics of Electrospun PHB Meshes
por: Kundrat, Vojtech, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_chm4u2gnbh7bu8gbr93lhu9ft5